Intelligence · Clinical Development
Pipeline search results
Programs matching “rituximab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 46 pipeline programs matching "rituximab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
APHP200026
Pari Pharma GmbH
Patients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.
1 trial -
NHL-014
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Diffuse Large B-Cell Lymphoma
1 trial -
OBINUTUZUMAB, RITUXIMAB
Pari Pharma GmbH
Idiopathic nephrotic syndrome (INS)
1 trial -
Rituximab
Hospital Authority, Hong Kong
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
1 trial -
Rituximab
United Therapeutics Europe Ltd
Follicular Lymphoma
1 trial -
Rituximab
Janssen Cilag International NV
Chronic Lymphocytic Leukemia
1 trial -
Rituximab
The First People's Hospital of Lianyungang
Refractory Myasthenia Gravis
1 trial -
Rituximab
The First People's Hospital of Lianyungang
Diffuse Large B-cell Lymphoma
3 trials -
Rituximab
Lxo Ireland Designated Activity Company
Lupus Nephritis
1 trial -
Rituximab
United Therapeutics Europe Ltd
Kidney Transplant Rejection
1 trial -
Rituximab (RTX)
Incyte
Diffuse Large B-cell Lymphoma
1 trial -
Rituximab 375 mg/m^2
Takeda
Mantle Cell Lymphoma
1 trial -
recombinant human thrombopoietin (rhTPO); rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Purpura
1 trial -
rhTPO in combination with Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Purpura
1 trial -
rituximab; recombinant human thrombopoietin (rhTPO)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Purpura
1 trial -
2021-SR-545
The First People's Hospital of Lianyungang
Lymphoma, Large B-Cell, Diffuse
1 trial -
APHP230848
Pari Pharma GmbH
Non-infectious active cryoglobulinemia vasculitis who are either refractory or intolerant to Rituximab
1 trial -
EBVALLO
Pierre Fabre Medicament
EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)
1 trial -
EPCORITAMAB, RITUXIMAB
Daiichi Sankyo
Hematological Malignancies
1 trial -
IIT2025111
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Waldenström Macroglobulinemia (WM)
1 trial -
RITUXIMAB, Golcadomide
Fondazione Telethon ETS
Diffuse Large B-cells non-Hodgkin Lymphoma
1 trial -
Rituximab
United Therapeutics Europe Ltd
Fatigue
1 trial -
Rituximab
BEONE MEDICINES AUS PTY LTD
Chronic Lymphocytic Leukemia
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Diffuse Large B Cell Lymphoma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.